Patients enrolled in this study were registered through the Memory Clinic at Landspitali University Hospital and the cognitive condition was assessed through the Minimum Data Set (MDS) for nursing homes. Genotypic data was then collects for the APP site A673T for all 1,763 patients. This data reveals that this site on APP is vital to the production of amyloid plaque, making it able to protect patients from the cognitive decline seen in Alzheimer’s and non-Alzheimer’s patients. These results make this mutation the first genetic variant discovered that can create a strong shield from Alzheimer’s disease. It also confirms the hypothesis that the pathogenesis of regular cognitive deterioration and Alzheimer’s disease may be partially related, suggesting that Alzheimer’s disease may be the driving force of the correlation between age and decline in cognitive function.
By Alec Waid, Intern Roskamp Institute